Female gender (P = 0.072), tumor response (P = 0.005), and gefitinib treatment (P>0.001) were significantly more frequent in the group of patients with EGFR mutations, whereas other characteristics showed no inter-group differences (Table 1). This evidence concerns the gene EGFR and neoplasm.